SCHEMBL4183869

SCHEMBL4183869

COc1cc(OC)c2c(=O)oc(-c3cc(C)c(OCCC4CNCCO4)c(C)c3)cc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 9/20 0.48
BRD2 P25440 4/20 0.39
BRD3 Q15059 4/20 0.39
BRDT Q58F21 4/20 0.39
IL17A Q16552 1/20 0.38
ADRA2C P18825 1/20 0.37
PDE6D O43924 1/20 0.36
PDE6A P16499 1/20 0.36
PDE6G P18545 1/20 0.36
PDE6B P35913 1/20 0.36
PDE6C P51160 1/20 0.36
PDE6H Q13956 1/20 0.36
PDE10A Q9Y233 1/20 0.36
HDAC1 Q13547 2/20 0.36
HDAC6 Q9UBN7 4/20 0.35
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL347749 0.81 BRD4 (0.58) BRD4BRD2BRD3BRDTIL17A
SCHEMBL4183865 0.81 BRD4 (0.38) BRD4BRD2BRD3BRDTABCB1
SCHEMBL348840 0.77 BRD4 (0.52) BRD4BRD2BRD3BRDTIL17A
SCHEMBL370550 0.76 BRD4 (0.56) BRD4BRD2BRD3BRDTIL17A
SCHEMBL370551 0.73 BRD4 (0.38) BRD4BRD2BRD3BRDTIL17A
SCHEMBL348377 0.71 XDH (0.51) BRD4ABCB1KDM4EMEN1ALDH1A1
SCHEMBL348539 0.71 BRD4 (0.49) BRD4BRD2BRD3BRDTABCB1
SCHEMBL4176421 0.70 MKNK1 (0.37) BRD4ADRA2CMKNK1SLC6A2SLC6A4
SCHEMBL20271941 0.65 BRD4 (1.00) BRD4BRD2BRD3BRDTABCB1
SCHEMBL30599697 0.65 BRD4 (1.00) BRD4BRD2BRD3BRDTABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410109-B2 Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices RESVERLOGIX CORP. (CA) 2013-04-02 US disclosed
US-20090029987-A1 Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices RESVERLOGIX CORP. (CA) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029987-A1 Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices VCAM1, ICAM1, TGFB1 BRD4 1004/4885BRD2 1414/4885BRD3 1125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.